Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Compares JNJ-79635322 with teclistamab in adults with relapsed or hard-to-treat multiple myeloma

Compares JNJ-79635322 with another antibody therapy in adults with relapsed multiple myeloma.

Key facts

Who runs it
Janssen Research & Development, LLC
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou, Wuhan, and Xi'an, ChinaSee the 11 sitesAlso in 14 other countries, 145 sites
Registry title
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Status
Recruiting
Phase
Phase 3
People taking part
400 people, planned
Started
4 Feb 2026
Expected to end
30 Sept 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • JNJ-79635322
  • Teclistamab
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple myeloma that came back or stopped responding after at least 3 earlier lines of treatment. It compares JNJ-79635322 with teclistamab.

Age
18 years or older
Sex
Men and women can join
Disease stage
Multiple myeloma with measurable disease at screening. The disease has grown or has not responded to the last line of treatment.
Earlier treatment
At least 3 earlier lines of myeloma treatment, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD) and an anti-CD38 antibody. Side effects from earlier cancer treatment must have settled to Grade 1 or better.

Main reasons for not taking part

  • Active hepatitis caused by an infection
  • Current or past myeloma in the brain or spinal cord area (central nervous system), or signs of meningeal involvement
  • Known or suspected allergy to the ingredients of JNJ-79635322 or teclistamab
  • Major surgery within 2 weeks before the first dose, or not yet recovered, or surgery planned during the trial
  • Live, weakened vaccine within 4 weeks before the first dose or during treatment

The registry criteria, word for word

Show all 11 criteriaShow less

Other criteria

  • Inclusion:
  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:; MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; Measurable disease at screening as assessed by central laboratory
  • Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody
  • Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria
  • Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better
  • Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration; Exclusion:
  • Active hepatitis of infectious origin
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
  • Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab
  • Major surgery, (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment, or during study treatment

Where in China

Also in 14 other countries, 145 sites

  • Peking University First HospitalBeijing, ChinaTaking people
  • Peking University People's HospitalBeijing, ChinaTaking people
  • Sichuan Provincial Peoples HospitalChengdu, ChinaTaking people
  • Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
  • First Affiliated Hospital of Zhejiang UniversityHangzhou, ChinaTaking people
  • Nanjing Drum Tower hospitalNanjing, ChinaTaking people
  • The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaTaking people
  • Shanghai Fourth People's HospitalShanghai, ChinaTaking people
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
  • Wuhan Tongji Hospital Tongji Medical CollegeWuhan, ChinaTaking people
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

The 2 groups in the trial

  • JNJ-79635322Treatment being tested

    Participants will receive subcutaneous (SC) dose of JNJ-79635322 until progressive disease (PD) or intolerable toxicity.

  • Anti BCMAxCD3 Bispecific AntibodyExisting treatment, for comparison

    Participants will receive teclistamab (an Anti BCMAxCD3 bispecific anitbody) as a SC injection until PD or intolerable toxicity.

    Treatment: Teclistamab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
Plain-language title
Compares JNJ-79635322 with teclistamab in adults with relapsed or hard-to-treat multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 November 2026